2024-03-18

1. Summary of the week

From March 9 to 15, a total of 13 licensing and cooperation agreements were signed globally. In the China Biotech Industry, 2 licensing and cooperation deals were sealed. The licensing and cooperation deal between Biotheus and Hansoh Pharmaceutical tops this week with a total deal amount of $706.5 million for the PM1080-ADC, which is in the pre-clinical stage. As of March 15, this deal has the highest total deal amount for 2024 China Domestic Licensing transactions. Meanwhile, in the global setting, the cooperation agreement between Sosei and Boehringer Ingelheim tops this week with an upfront payment of $27 million and a total amount of $816.5 million for 2 assets, the HTL0048149 and HTL0041178.

2024年3月9日-15日，全球市场共有13项资产授权和合作交易。中国市场共有2项。普米斯独家授权翰森制药使用抗EGFR/cMet双特异抗体HS-20117/PM1080用于开发抗体药物偶联物，交易总金额预计可达706.5百万美元，也是今年以来国内资产交易中金额最大的一起。全球市场则有11项资产授权和合作交易。最大的交易来自Sosei和勃林格殷格翰达成的共同开发和商业化Sosei的潜在“first-in-class”GPR52激动剂候选疗法交易，首付款27百万美元，总交易金额达816.5百万美元。

2. Licensing Deals

2a. China section

2b. Global section

3.M&A Deals

4. Top Deals of the year 2024

5. 2019-2023 China Innovative Drug Licensing Transactions

About YAFO Capital

雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。

Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions in the past three years. For more information, please visit http://www.yafocapital.com

ACCESS CHINA